At Ironwood, we're focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders.

Being a shareholder of Ironwood is about more than owning our shares, it's about being an owner of our business. We want you to understand our decisions and actions, and we will strive to effectively communicate the opportunities and risks involved in our business at each step along the way.

Among Ironwood's shareholders are our own employees, and this ownership mentality influences our operations. Ironwoodians are careful stewards of the company's resources, whether making a go/no-go decision on a discovery program or booking travel to a conference. Every program is challenged to earn its way forward, and every employee is challenged to earn the right to pursue the goal we all – employees and other shareholders alike – aspire to achieve: making medicines that help people lead better lives.

Press Releases

05.14.2013
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013

05.07.2013
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference

04.23.2013
Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update

04.02.2013
Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call

03.04.2013
Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors

View all releases »




Current Prices
Quotes delayed 20 minutes
IRWD NASDAQ $14.39   - 0.21


2013 Proxy Statement | 04.12.2013
View/Download PDF Version

2012 10-K | 02.22.2013
View/Download PDF Version

Latest 10-Q | 04.23.2013
View Filing


Ironwood IR contact
Meredith Kaya
Associate Director, Investor Relations
T 617.374.5082
E mkaya@ironwoodpharma.com
Auditors
Ernst & Young
200 Clarendon Street
Boston, MA 02116
T 617.266.2000
Transfer agent
Computershare Investor Services
P.O.Box 43078
Providence, RI 02940
T 800.662.7232
www.computershare.com